File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: An analysis from the CARDS trial

TitleTotal soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: An analysis from the CARDS trial
Authors
Issue Date2011
PublisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/
Citation
Diabetes, 2011, v. 60 n. 9, p. 2379-2385 How to Cite?
AbstractOBJECTIVE - Circulating levels of soluble receptor for advanced glycation end products (sRAGE) likely comprise both a secreted isoform (esRAGE) and wild-type RAGE cleaved from the cell membrane. Both sRAGE and esRAGE have been proposed as biomarkers of cardiovascular disease (CVD), but prospective data are limited. We examined the relationship of sRAGE and esRAGE to incident coronary heart disease (CHD) and stroke in type 2 diabetic patients followed for 3.9 years in a trial of atorvastatin: the Collaborative Atorvastatin Diabetes Study (CARDS). RESEARCH DESIGN AND METHODS - We used a nested case-control design sampling all incident cases of CVD with available plasma and randomly selecting three control subjects, who were free of CVD throughout follow-up, per case. Analysis was by Cox regression with adjustment for treatment allocation and relevant covariates. RESULTS - sRAGE and esRAGE were strongly correlated (r = 0.88) and were both higher in those with lower BMI (P < 0.001), higher adiponectin (P < 0.001), lower estimated glomerular filtration rate (P = 0.009), and white ethnicity (P < 0.001). Both sRAGE and esRAGE were associated with incident CHD events, independently of treatment allocation and the above factors; hazard ratio (HR) = 1.74 (95% CI 1.25-2.41; P = 0.002) for a doubling of the sRAGE level; HR = 1.45 (1.11-1.89; P = 0.006) for a doubling of the esRAGE level. There was no significant association with stroke; HR for sRAGE = 0.66 (0.38-1.14). Atorvastatin, 10 mg daily, did not alter sRAGE. CONCLUSIONS - Higher levels of sRAGE and esRAGE are associated with incident CHD but not stroke in type 2 diabetes. © 2011 by the American Diabetes Association.
Persistent Identifierhttp://hdl.handle.net/10722/163401
ISSN
2015 Impact Factor: 8.784
2015 SCImago Journal Rankings: 5.185
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorColhoun, HMen_US
dc.contributor.authorBetteridge, DJen_US
dc.contributor.authorDurrington, Pen_US
dc.contributor.authorHitman, Gen_US
dc.contributor.authorNeil, Aen_US
dc.contributor.authorLivingstone, Sen_US
dc.contributor.authorCharltonMenys, Ven_US
dc.contributor.authorBao, Wen_US
dc.contributor.authorDemicco, DAen_US
dc.contributor.authorPreston, GMen_US
dc.contributor.authorDeshmukh, Hen_US
dc.contributor.authorTan, Ken_US
dc.contributor.authorFuller, JHen_US
dc.date.accessioned2012-09-05T05:30:55Z-
dc.date.available2012-09-05T05:30:55Z-
dc.date.issued2011en_US
dc.identifier.citationDiabetes, 2011, v. 60 n. 9, p. 2379-2385en_US
dc.identifier.issn0012-1797en_US
dc.identifier.urihttp://hdl.handle.net/10722/163401-
dc.description.abstractOBJECTIVE - Circulating levels of soluble receptor for advanced glycation end products (sRAGE) likely comprise both a secreted isoform (esRAGE) and wild-type RAGE cleaved from the cell membrane. Both sRAGE and esRAGE have been proposed as biomarkers of cardiovascular disease (CVD), but prospective data are limited. We examined the relationship of sRAGE and esRAGE to incident coronary heart disease (CHD) and stroke in type 2 diabetic patients followed for 3.9 years in a trial of atorvastatin: the Collaborative Atorvastatin Diabetes Study (CARDS). RESEARCH DESIGN AND METHODS - We used a nested case-control design sampling all incident cases of CVD with available plasma and randomly selecting three control subjects, who were free of CVD throughout follow-up, per case. Analysis was by Cox regression with adjustment for treatment allocation and relevant covariates. RESULTS - sRAGE and esRAGE were strongly correlated (r = 0.88) and were both higher in those with lower BMI (P < 0.001), higher adiponectin (P < 0.001), lower estimated glomerular filtration rate (P = 0.009), and white ethnicity (P < 0.001). Both sRAGE and esRAGE were associated with incident CHD events, independently of treatment allocation and the above factors; hazard ratio (HR) = 1.74 (95% CI 1.25-2.41; P = 0.002) for a doubling of the sRAGE level; HR = 1.45 (1.11-1.89; P = 0.006) for a doubling of the esRAGE level. There was no significant association with stroke; HR for sRAGE = 0.66 (0.38-1.14). Atorvastatin, 10 mg daily, did not alter sRAGE. CONCLUSIONS - Higher levels of sRAGE and esRAGE are associated with incident CHD but not stroke in type 2 diabetes. © 2011 by the American Diabetes Association.en_US
dc.languageengen_US
dc.publisherAmerican Diabetes Association. The Journal's web site is located at http://diabetes.diabetesjournals.org/en_US
dc.relation.ispartofDiabetesen_US
dc.subject.meshAgeden_US
dc.subject.meshBiological Markers - Blooden_US
dc.subject.meshCase-Control Studiesen_US
dc.subject.meshCoronary Disease - Blood - Diagnosisen_US
dc.subject.meshDiabetes Mellitus, Type 2 - Blooden_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPredictive Value Of Testsen_US
dc.subject.meshReceptors, Immunologic - Blooden_US
dc.subject.meshStroke - Blood - Diagnosisen_US
dc.titleTotal soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: An analysis from the CARDS trialen_US
dc.typeArticleen_US
dc.identifier.emailTan, K:kcbtan@hku.hken_US
dc.identifier.authorityTan, K=rp00402en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.2337/db11-0291en_US
dc.identifier.pmid21771973-
dc.identifier.scopuseid_2-s2.0-80052885987en_US
dc.identifier.hkuros203430-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-80052885987&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume60en_US
dc.identifier.issue9en_US
dc.identifier.spage2379en_US
dc.identifier.epage2385en_US
dc.identifier.isiWOS:000294699600021-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridColhoun, HM=7003466904en_US
dc.identifier.scopusauthoridBetteridge, DJ=34973752700en_US
dc.identifier.scopusauthoridDurrington, P=7101726771en_US
dc.identifier.scopusauthoridHitman, G=7006269069en_US
dc.identifier.scopusauthoridNeil, A=17342746600en_US
dc.identifier.scopusauthoridLivingstone, S=7004658349en_US
dc.identifier.scopusauthoridCharltonMenys, V=14008536100en_US
dc.identifier.scopusauthoridBao, W=35168457200en_US
dc.identifier.scopusauthoridDeMicco, DA=15519081900en_US
dc.identifier.scopusauthoridPreston, GM=7101669019en_US
dc.identifier.scopusauthoridDeshmukh, H=24437907500en_US
dc.identifier.scopusauthoridTan, K=8082703100en_US
dc.identifier.scopusauthoridFuller, JH=7202037574en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats